Aurinia Pharmaceuticals AUPH Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Aurinia Pharmaceuticals (AUPH) reported accounts payable and other current liabilities (note 11) of $58.2M in Q1 2026.
- How has Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
- Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11) increased by 37.4% year-over-year, from $42.35M to $58.2M.
- What is the long-term trend for Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 21.9% compound annual growth rate (CAGR), from $24.8M to $66.62M.